Alzheimer's drug slows functional decline
Use of tarenflurbil in patients with mild Alzheimer's disease appears to slow decline in functional ability compared with placebo, a UK phase II trial shows.
In patients with mild disease taking 800mg of tarenflurbil twice a day, there was a 46% lower rate of decline on the activities of daily living scale and a 36% lower rate of decline in global function, compared with placebo.
But there was no benefit of tarenflurbil at either 400mg or 800mg in patients with moderate Alzheimer's disease.
Lancet Neurology 2008; 30 April early online publication